natgillin/translations-raw huggingface dataset:
In another embodiment, said incision line has a shape that is circular, oval, linear, arc of circle, square with rounded corners, rectangular with rounded corners, hexagonal with rounded corners, or a finite curved line with an irregular shape, allowing the container to be removed outside said partially detachable packaging section. 
Uzorak ambalažnog pakiranja u skladu s bilo kojim zahtjevima 12 do 14, naznačen time što navedena rezna linija ima oblik kruga, ovala, linije, luka kruga, kvadrata sa zaobljenim vrhovima, pravokutnika sa zaobljenim vrhovima, šesterokuta sa zaobljenim vrhovima ili čak zakrivljene završeno linije nepravilnog oblika, omogućavajući vađenje navedenog spremnika van navedene djelomično odvojive sekcije (4) ambalažnog pakiranja.
The method according to claim 1, 2, 3, 4 or 5, wherein the at least one secondary anti-retroviral or other adjunctive therapeutic agent is selected from the group consisting of: protease inhibitors, nucleoside reverse transcriptase, non-nucleoside reverse transcriptase inhibitors, combination drugs, entry and fusion inhibitors, acyclovir, adefovir dipivoxil, aldesleukin, amphotericin b, azithromycin, calcium hydroxylapatite, clarithromycin, doxorubicin, dronabinol, entecavir, epoetin alfa, etoposide, fluconazole, ganciclovir, immunoglobulins, interferon alfa-2, isoniazid, itraconazole, megestrol, paclitaxel, peginterferon alfa-2, pentamidine, poly-1-lactic acid, ribavirin, rifabutin, rifampin, somatropin, testosterone, trimetrexate, valganciclovir; integrase inhibitors, microbicides, and IL-2. 
Uporaba prema zahtjevu 3, gdje se barem jedno dodatno anti-retrovirusno ili drugo dopunsko terapijsko sredstvo odabire iz skupine koju čine: inhibitori proteaze, nukleozidni inhibitori reverzne transkriptaze, ne-nukleozidni inhibitori reverzne transkriptaze, kombinirani lijekovi, inhibitori ulaza i fuzije, aciklovir, adefovir dipivoksil, aldesleukin, amfotericin b, azitromicin, kalcijev hidroksilapatit, klaritromicin, doksorubicin, dronabinol, entekavir, epotein alfa, etopozid, flukonazol, ganciklovir, imunoglobulini, interferon alfa-2, izoniazid, ribavirin, rifabutin, rifampin, somatropin, testosteron, trimetreksat, valganciklovir; inhibitori integraze, mikrobicidi, i IL-2.
A combination according to claim 13, wherein the pain is inflammatory pain. 
Kombinacija prema zahtjevu 9, naznačena time da bol je upalna bol.
The process according to claim 10, wherein the calcium carbonate is first contacted with the at least one acid having a pKa of less than or equal to 2.5 and after 80 % of the total amount of said at least one acid having a pKa of less than or equal to 2.5 have been added, the calcium carbonate is contacted with the at least one water soluble non-polymeric organic and/or inorganic weak acid and/or hydrogen salt of said at least one water soluble non-polymeric organic and/or inorganic weak acid. 
Postupak prema zahtjevu 10, naznačen time da se kalcijev karbonat prvo dovodi u kontakt sa najmanje jednom kiselinom koja ima pK, od manje od ili jednako 2.5 i nakon što je dodano 80 % ukupne količine navedene najmanje jedne kiseline koja ima pK, od manje od ili jednako 2.5, kalcijev karbonat se dovođi u kontakt sa barem jednom u vodi topivom ne-polimernom organskom i/ili anorganskom slabom kiselinom i/ili vodikovom soli navedene barem jedne u vodi topive ne-polimerne organske i/ili anorganske slabe kiseline.
The oligonucleotide for use according to any one of clauses 1 to 8, wherein said oligonucleotide is repetitively administered as a single exposure on separate occasions 4 to 8 weeks apart. 
Oligonukleotid za primjenu prema patentnom zahtjevu 1, naznačen time, što se predmetni oligonukleotid opetovano primjenjuje u obliku jednokratne izloženosti u više navrata u razmaku od 4 do 8 tjedana.
In view of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are generally employed. 
Kako bi se olakšala njihova aplikacija, tablete i kapsule predstavljaju najpogodniji oralni oblik za doziranje, u kojem se slučaju općenito rabi kruti farmaceutski nosač.
A cancer chemotherapeutic agent according to (3) above, wherein the anti-cancer agent is one or more species selected from the group consisting of Paclitaxel, Docetaxcel, Pemetrexed, 5-FU, Cisplatin, Oxaliplatin, Cyclophosphamide, and Irinotecan. 
Protutumorsko kemoterapijsko sredstvo u skladu s patentnim zahtjevom 2, naznačeno time, da je protutumorsko sredstvo jedna ili više vrsta odabrana iz skupine koja se sastoji od cisplatina i oksaliplatina. 4. Protutumorsko kemoterapijsko sredstvo u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačeno time, da je 15
Such liquid preparations may contain conventional additives such as suspending agents, for example, sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxymethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats; emulsifying agents, for example, lecithin, sorbitan mono-oleate or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters, propylene glycol or ethyl alcohol; or preservatives, for example, methyl or propyl p-hydroxybenzoates or sorbic acid. 
Takvi tekući pripravci mogu sadržavati uobičajene aditive, poput sredstava za suspendiranje, primjerice sorbitolni sirup, metilcelulozu, glukozni odnosno šećerni sirup, želatinu, hidroksimetilcelulozu, karboksimetilcelulozu, aluminijsko-stearatni gel ili hidrogenirane jestive masti; emulgatore, primjerice lecitin, sorbitan-monooleat ili arapsku gumu; nevodene vehikulume (koji mogu uključivati jestiva ulja), primjerice bademovo ulje, frakcionirano kokosovo ulje, uljne estere, propilen-glikol ili etil-alkohol; ili konzervanse, primjerice metil- ili propil-p-hidroksibenzoate ili sorbinsku kiselinu.
In some embodiments, the retroviral kits comprise (a) an integration-defective retroviral vector transfer cassette lacking a functional PPT; and (b) a packaging cell line comprising at least one construct encoding one or more proteins required for the retroviral vector to be packaged. 
(a) retrovirusnu vektorsku kazetu za prijenos manjkavu u integraciji kojoj nedostaje 3'-PPT; i (b) staničnu liniju za pakiranje koja sadrži najmanje jedan konstrukt koji kodira jedan ili više proteina potrebnih za pakiranje retrovirusnog vektora.
The solution was then transferred to a separatory funnel and organics were extracted with 20 mL EtOAc. The organic extract was then washed with saturated sodium bicarbonate and water until the pH of the water washes was approximately 7. 
Otopina je tada bila premještena u lijevak za odjeljivanje 1 organske tvari su bile odvojene s 20 mL EtOAc, Odvojena organska tvar je bila tada isprana sa zasićenim natrij bikarbonatom i vodom sve dok voda od ispiranja nije imala pH približno 7.
The method according to claim 11 or 14, wherein the reperfusion injury is myocardial reperfusion injury or acute myocardial infarction. 
Uporaba prema patentnom zahtjevu 19 naznačena time što ishemijska i/ili reperfuzijska ozljeda je ishemija miokarda, reperfuzijska ozljeda miokarda ili akutni infarkt miokarda.
represents a substituted or unsubstituted imidazole, 
predstavlja supstituirani ili nesupstituirani imidazol;
A method according to claim 1, wherein said atmospheric pressure plasma is applied using single jet electrode with a distance of at least 3 mm from said polyolefinic material. 
Metoda u skladu sa patentnim zahtjevom 1, gdje navedena plazma na atmosferskom pritisku je primijenjena korištenjem elektrode sa pojedinačnim mlazom sa udaljenosti od najmanje 3 mm od navedenog poliolefinskog materijala.
The kit as claimed in Claim 12, wherein the first and second parts are independently in form of a tablet, capsule or granule. 
Garnitura za uporabu prema zahtjevu 12, naznačena time, da prvi dio i drugi dio su neovisno u obliku tablete, kapsule ili granule.
The composition of any one of claims 1 to 3, wherein the amino acid is selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, pyrrolysine, selenocysteine, serine, threonine, tryptophan, tyrosine and valine. 
Kompozicija sukladno zahtjevu 1 ili 2, pri tome je aminokiselina odabrana iz skupine koja se sastoji od alanina, arginina, asparagina, asparaginske kiseline, cisteina, glutaminske kiseline, glutamina, glicina, histidina, izoleucina, leucina, lizina, metionina, fenilalanina, prolina, pirolizina, selenocisteina, serina, treonina, triptofana, tirozina i valina.
Use according to claim 7, wherein the composition further comprises an osmolality adjusting agent selected from the group consisting of monosaccharides, disaccharides, oligosaccharides, and low molecular weight polyols. 
Jota-karagenan u antivirusno učinkovitoj količini za upotrebu prema patentnom zahtjevu 7, naznačeno time da pripravak nadalje sadrži sredstvo za podešavanje osmolalnosti odabrano iz skupine koju čine monosaharidi, disaharidi, oligosaharidi i polioli male molekulske mase.
The composition according to claim 1, wherein the composition is in an oral dosage form selected from the group consisting of tablets, capsules, slurries, sachets, suspensions and dragees. 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što se pripravak u oralnom doziranju bira iz skupine koju čine tablete, kapsule, guste suspenzije, vrećice, suspenzije i dražeje.
The titled compound is prepared analogously to 4-fluoro-3-methoxy-benzenesulfonyl chloride (Intermediate 102a) by replacing 4-fluoro-3-methoxyaniline with 2-chloro-5-methoxy-phenylamine. 
Naslovni spoj je proizveden analogno 4-fluor-3-metoksi-benzensulfonil kloridu (intermedijat 1024) zamjenom 4-fluor-3-metoksianilina s 2-klor-5-metoksi-fenilaminom.
The method according to claim 7, wherein the hyaluronic acid has an average molecular weight ranging from 50,000 to 10,000,000 Daltons. 
Postupak prema patentnom zahtjevu 1, naznačen time što hijaluronska kiselina ima prosječnu molekularnu težinu u rasponu od 50 000 do 10 000 000 Daltona.
Then the catalyst is filtered off and the filtrate evaporated at 40°. To the residue (30 g) 600 ml t-butyl methyl ether are dropped at RT, the suspension filtered and the residue washed with 300 ml TBME. 
Zatim se katalizator ukloni filtriranjem i filtrat evaporira na 40 "C. Ostatku (30 g) se ukapa 600 ml t-butil metil etera na RT, suspenzija se filtrira i ostatak se ispere s 300 ml TBME.
A compound of claim 1 having Formula (II) or a pharmaceutically acceptable salt thereof, wherein R2 is selected from hydrogen and haloalkyl; and R3 is selected from hydrogen and halo; or R2 and R3, together with the carbon atoms to which they are attached, form a five- or six-membered aromatic or non-aromatic ring carbocyclic ring; 
je izabran između vodika i haloalkil; i je izabran između vodika i halo; ili i R3, zajedno s atomima ugljika na koje su vezani, formiraju petero- ili šesteročlani aromatski ili nearomatski karbociklički prsten;
According to a further embodiment of the method, the flatness measuring device can be arranged to measure the profile of the roll. 
Postupak prema zahtjevima od 16 do 19, naznačen time, da je sredstvo za mjerenje plosnatosti (9) namješteno za mjerenje profila valjka (3).
a cutting edge portion (112) at the distal end of the shaft, wherein the cutting edge portion comprises at least a first and a second bend (102,104) and a distal end point (106); 
- < odsječak Trezne oštrice (112) na distalnom kraju osovine, pri čemu odsječak rezne oštrice sadrži najmanje prvi i drugi savijeni dio (102, 104) i točku distalnog kraja (106);
Indeed there is evidence that lithium, an uncompetitive inhibitor of GSK3B, enhances neuritogenesis in some models and also increases neuronal survival, through the induction of survival factors such as Bc1-2 and the inhibition of the expression of proapoptotic factors such as P53 and Bax. 
I doista, postoji dokaz da litij, nekompetitivni inhibitor GSK3R, pojačava neuritogenezu u nekim modelima, a također povećava i preživljenje neurona, indukcijom čimbenika preživljavanja, poput Bcl-2, te inhibicijom eksprezije proapoptotskih čimbenika, poput P53 i Bax.
A combination according to claim 21, wherein said effective therapeutic amounts of ET-743 and PLD are provided as separate medicaments for the administration at the same time or at different times. 
Kombinacija prema patentnom zahtjevu 21, naznačena time što su navedene efikasne količine ET-743 i PLD osigurane kao odvojeni lijekovi za primjenu u isto vrijeme ili u različita vremena.
A host cell comprising the nucleic acid or the expression vector according to claim 4, wherein said host cell is not a human embryonic stem cell. 
Stanica domaćin koja se sastoji od nukleinske kiseline ili ekspresijskog vektora u skladu s patentnim zahtjevom 6, pri čemu navedena stanica domaćin nije ljudska embrionska matična stanica.
Compound of formula II provides a convenient means to purify crude compound of formula Ia which was obtained as a mixture of alpha and beta anomers. 
Spoj formule II osigurava pogodna sredstva za prečišćavanje sirovog spoja formule Ia koji je dobijen kao smjesa alfa 1 beta anomera.
Obviously a residual content also represents a vast, and thus a loss for the user of the apparatus. 
Očigledno je da zaostali sadržaj također predstavlja otpad, i stoga gubitak za korisnika aparata.
Accordingly, in one embodiment, the acute lymphoblastic leukemia (ALL) is refractory to chemotherapy and/or allogeneic HSCT in pediatric patients non-eligible or no longer eligible for allogeneic HSCT. 
Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je navedena akutna limfoblastična leukemija (ALL) refrakterna i/ili recidiv ALL.
(viii) it has a sialylation pattern which is altered compared to the sialylation pattern of at least one protein molecule composition of the same protein molecule isolated from ATCC No. 
(viii) ima primijenjeni uzorak sijaliliranja u usporedbi s uzorkom sijaliliranja za pripravak s najmanje jednom molekulom proteina za istu molekulu proteina koja je izolirana iz ATCC No.
The method of claim 15, wherein the semicrystalline polymer admixed in step (b) comprises a polyolefin, preferably wherein the polyolefin comprises LDPE; or wherein 
Postupak u skladu s patentnim zahtjevom 15, naznačen time, da je (a) polukristalni polimer pomiješan u koraku (b) sadržava poliolefin, pri čemu je poželjno da poliolefin sadržava LDPE; ili
A high purity diaminophenothiazinium compound according to claim 1, having the following formula: 
Diaminofenotiazinski spoj visoke čistoće prema zahtjevu 2, naznačen time, da:
Covering, in particular a floor covering, consisting of mutually coupled panels as claimed in any of the foregoing claims. 
Pokrov, posebno podni pokrov, koji se sastoji od međusobno povezanih ploča (1, 42, 43, 46, 53, 57) u skladu s bilo kojim od prethodnih patentnih zahtjeva.
The composition of any one of claims 1-5, wherein the antibody or antibody fragment comprises 
Kompozicija iz bilo kojeg od patentnih zahtjeva 1-5, gdje antitijelo ili fragment antitijela sadrži
The high-printability coated paper according to claim 1, characterized in that said paper substrate has a grammage comprised between 85 g/m2 and 400 g/m2. 
Premazani papir visoke printabilnosti u skladu s patentnim zahtjevom 1, naznačen time, da je gramatura navedene papirnate podloge u rasponu od 85 g/m2 do 400 g/m2.
Process according to one of claims 2 to 12, wherein the processing agent is added in amounts of up to 8 wt.% based on the dry weight of the slurry, preferably in amounts from 0.01 wt.% to about 5 wt.%, more preferably from about 0.05 wt.% to about 4 wt.%, still more preferably from about 0.4 wt% to about 3wt.%, based on the dry weight of the slurry. 
Postupak prema jednom od zahtjeva 1 do 11, naznačen time da se sredstvo za obradu dodaje u količinama od 0.01 tež.% do oko 5 tež.%, poželjnije od oko 0.05 tež.% do oko 4 tež.%, još poželjnije od oko 0.4 tež.% do oko 3 tež.%, bazirano na suhoj težini suspenzije.
The method of claim 1, wherein the cancer is colorectal cancer. 
Sastav za uporabu u skladu s patentnim zahtjevom 6, pri čemu je karcinom kolorektalni karcinom.
is 1 to 4 amino acid residues in length; 
je duljine 1 do 4 ostatka amino kiseline;
It is also frequently detrimental, particularly in activities such as tennis or golf which require a reliable grip on equipment, to have an applied sunscreen formulation remain lubricious after application or become lubricious when mixed with perspiration or other moisture. 
Također je često štetno, naročito kod aktivnosti kao što su tenis ili golf, koje zahtijevaju sigurno držanje opreme, da naneseni pripravak za zaštitu od sunca ostane klizav nakon primjene ili postane klizav kad se pomiješa sa znojem ili drugom vlagom.
The method of any one of paragraphs 14-19, wherein the administering to said infant occurs at one or more times selected from the group consisting of immediately after birth, about 2 weeks after birth, about 4 weeks after birth, about 6 weeks after birth, about 2 months after birth, about 3 months after birth, about 4 months after birth, about 6 months after birth, about 9 months after birth, and about 12 months after birth. 
Pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što se primjenu na navedenom dojenčetu provodi jednom ili više puta, što se bira iz skupine koju čine neposredno nakon rođenja, 2 tjedna nakon rođenja, 4 tjedna nakon rođenja, 6 tjedana nakon rođenja, 2 mjeseca nakon rođenja, 3 mjeseca nakon rođenja, te 4 mjeseca nakon rođenja.
compressing the blend from the step (6) into tablets; and 
komprimiranje smjese iz (5) u tablete; i
B2 agonists such as salmeterol; 
B2 agonista kao što je salmeterol;
The preventative or therapeutic agent against infections in humans, animals and plants according to Claim 5 or 6, which is applied to an affected area in the treatment of periodontal disease after the affected area is disinfected with a bactericidal disinfectant. 
Preventivno ili terapijsko sredstvo protiv infekcija kod ljudi, životinja i biljaka u skladu s patentnim zahtjevom 3 ili 4, namijenjeno liječenju bolesti periodonta, gdje se navedeno sredstvo primjenjuje na oboljelom području nakon dezinficiranja oboljelog područja baktericidnim dezinficijensom.
A composition comprising the isolated IL-23p19 antibody fragment according to claim 1 or 5 and at least one pharmaceutically acceptable carrier or diluent. 
(a) kodira najmanje jedno izolirano IL-23p19 antitijelo prema patentnom zahtjevu 1 ili patentnom zahtjevu 2;
A is C1-6 alkyl, phenyl, a naphthyl ring, monocyclic or bicyclic C3-10 cycloalkyl, monocyclic or bicyclic C2-10 heterocycloalkyl, or monocyclic or bicyclic C1-10heteroaryl; each of which is optionally substituted with 1, 2, 3, 4, or 5 independently selected R5 groups; or 
A je C1-6 alkil, fenil, prsten naftila, monociklički ili biciklički C3-10 cikloalkil, monociklički ili biciklički C2-10 heterocikloalkil, ili monociklički ili biciklički C1-10 heteroaril; od kojih je svaki opcijski supstituiran sa 1, 2, 3, 4, ili 5 nezavisno izabranih R5 grupa; ili
90, which fragment begins with an amino acid at a position from the range hTRAIL95 to hTRAIL121, inclusive, and ends with the amino acid at the position hTRAIL281, or a homolog of said functional fragment having at least 70% sequence identity, preferably 85% identity, wherein said functional fragment or homolog thereof are capable of inducing apoptotic signal in mammalian cells upon binding to its receptors on the surface of the cells, and at least one domain (b) which is the sequence of a cytolytic effector peptide with an amphipathic alpha-helix conformation forming pores in the cell membrane, 
90, koji fragment počinje s amino kiselinom na položaju iz raspona hTRAIL95 do hTRAIL121, uključivo, te završava s amino kiselinom na položaju hTRAIL281, ili homolog navedenog funkcionalnog fragmenta ima barem 70% identičnosti sekvence, poželjno 85% identičnosti, pri čemu su navedeni funkcionalni fragment ili njegov homolog sposobni inducirati apoptotični signal u stanicama sisavaca nakon vezanja na njegove receptore na površini stanica, te uzvojnice koja stvara pore u staničnoj membrani, naznačen time da je sekvenca domene (b) vezana na C-terminalni kraj ili N-terminalni kraj domene (a).
The pharmaceutical composition of claim 21, wherein said additional therapeutic agent is selected from the group consisting of interferons, ribavirin analogs, NS3 protease inhibitors, NS5a inhibitors, NS5b polymerase inhibitors, alpha-glucosidase 1 inhibitors, cyclophilin inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV. 
Farmaceutska smjesa iz patentnog zahtjeva 21, gdje je pomenuto dodatno terapijsko sredstvo izabrano iz skupine koja se sastoji od interferona, analoga ribavirina, NS3 inhibitora proteaze, NS5a inhibitora, NS5b inhibitora polimeraze, inhibitora alfa glukozidaze 1, inhibitora ciklofilina, hepatoprotektora, nenukleozidnih HCV inhibitora, i drugih lijekova za liječenje Hepatitisa C.
CBD alone or in combination with THCV for use in the treatment of generalised seizures and / or partial seizure as claimed in claim 1 or 2 wherein the CBD is present in amount which provides a daily dose of at least 400mg. 
CBD za primjenu u liječenju parcijalnih napadaja prema zahtjevu 5, naznačen time da je THCV prisutan u količini koja osigurava dnevnu dozu od najmanje 15 mg.
3-Amino-5,6-bis-trifluoromethyl-pyridine-2-carboxylic acid ((R)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide or a pharmaceutically acceptable salt thereof. The method according to claim 1 further comprising administration of another drug substance. 
Spoj prema zahtjevu 7, naznačen time, da je to: 3-amino-5,6-bis-trifluorometil-piridin-2-karboksilna kiselina-((R)-(3,3,3-trifluoro-2-hidroksi-2-metil-propil)-amid, ili njegova farmaceutski prihvatljiva sol.
In another aspect the present invention provides a pharmaceutical formulation comprising a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for use in the treatment or prophylaxis of atherosclerosis by preventing and reducing the formation of new atherosclerotic lesions and/or plaques and/or by preventing or slowing progression of existing lesions and plaques. 
. Upotreba spoja formule (I) kako je definirano u bilo kojem zahtjevu 1 do 10, ili njegove farmaceutski prihvatljive soli, naznačena time, da se navedeni spoj upotrebljava za proizvodnju lijeka za liječenje ili profilaksu ateroskleroze pomoću prevencije i/ili smanjenja postupka stvaranja novih ateroskleroznih lezija ili plakova i/ili pomoću prevencije ili usporavanja napredovanja postojećih lezija i plakova.
The antibody of claim 4, wherein the VH consists of the amino acid sequence set forth in SEQ ID NO:10 and the VL consists of the amino acid sequence set forth in SEQ ID NO:13. 
Protutijelo ili njegov fragment koji veže a-sinuklein u skladu s patentnim zahtjevom 1, naznačen time da VH regija obuhvaća aminokiselinske odsječke od SEQ ID NO: 10 i VL regija sadržava aminokiselinske odsječke od SEQ ID NO: 13.
The immunogenic composition according to claim 19, wherein the M72 related antigen consists of the amino acid sequence of SEQ ID No: 3. 
Imunogeni pripravak u skladu s patentnim zahtjevom 19, naznačen time što antigen povezan s M72 ima aminokiselinski slijed sa SEQ ID No: 3.
A solid oral extended release pharmaceutical dosage form of claim 1, wherein the composition comprises 12 mg hydromorphone hydrochloride, and at least about 92 % (by wt) polyethylene oxide. 
Oralni farmaceutski oblik davanja s produljenim otpuštanjem u krutom stanju prema zahtjevu 1, naznačen time da sastav sadrži 10 mg oksikodon hidroklorida, i barem oko 85% (težine) polietilen oksida.